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Hepatitis B virus (HBV) is a hepatotropic, non-cytopathic DNA virus that can 
cause acute or chronic hepatitis. Epidemiologically, the majority of HBV 
infections are concentrated in the developing regions of Asia and Africa. Acute 
HBV is not the major contributor to HBV mortality and morbidity, as the patient 
is able to clear the virus and the disease resolves itself in most cases. In contrast, 
chronic HBV is a serious global health problem as a proportion of patients will 
go on to develop cirrhosis of the liver and eventually hepatocellular carcinoma 
(HCC) which is associated with significant global mortality rates.  
Chronic HBV is commonly transmitted vertically and results in prolonged liver 
inflammation and periods of high viral replication. As a result many patients 
must engage in long-term drug therapy to control viral replication and the 
clinical symptoms. The two main classes of antiviral treatments are interferon-
alpha (IFN-α) based therapy and nucleoside analogues (NA). IFN-α therapy 
works by modulating the intracellular immune response. The efficacy of IFN-α 
therapy is limited, with only 5-10% of patients successfully treated. Nucleoside 
analogues exert their effects by blocking the reverse transcriptase enzyme 
required for the production of new virions. The current nucleoside analogues 
inhibit the production of new virions, they do not however remove the 
transcriptional template of covalently closed circular DNA (cccDNA) and 
therefore upon treatment discontinuation there of a risk of viral rebound. As a 





The costs and emerging resistance associated with prolonged treatment are 
motivators for treatment discontinuation. However, when chronic patients 
discontinue their therapy more than 55% of the subjects experience viral rebound 
often associated with episodes of hepatic flare (HF) that might potentially be 
dangerous and which corresponds to an increase in serum alanine 
aminotransferase (ALT) levels.  
The aim of this study is to increase our understanding of the immune profile 
associated with chronic HBV (CHB) patients who experience viral rebound or 
viral control upon the discontinuation of HBV antiviral therapy. In this study, the 
patients are on Lamivudine and Tenofovir, two nucleoside analogues. The 
patients are studied longitudinally for two years, initially on combinational 
treatment, then stopping one treatment (Tenofovir) and then the other 
(Lamivudine), followed by a period of complete therapy withdrawal. By 
performing the sequential analysis of virological and immunological parameters 
in these patients, we aim to increase our understanding of the immunological 
events preceding and during viral rebound. It is predicted that specific features of 
the adaptive immune response play a crucial role in determining the development 
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Hepatitis B Viral Infection 
 
Hepatitis B virus (HBV) is a non-cytopathic DNA virus that can cause acute or 
chronic hepatitis, preferentially infecting the principal cells of the liver, 
hepatocytes. Hepatitis B virus has a wide range of clinical outcomes, varying 
from acute self-limiting infection to chronic persistent infection. Acute infection 
usually ends after 4-8 weeks of self-limiting disease and sometimes jaundice, 
whereas chronically infected patients typically do not develop clinical symptoms 
upon infection. Chronic infection is associated with fluctuations of HBV-DNA, 
varying from zero to 1011 copies/ml of serum (Dienstag, 2008). These 
fluctuations of viral DNA can be associated with hepatic injury, indicated by 
elevated levels of alanine aminotransferase (ALT). The elevated levels of ALT 
are representative of liver injury exacerbation and follows the accumulation of 
HBV-DNA and HBV antigens in the serum (Maruyama, Iino, Koike, Yasuda, & 
Milich, 1993; Mels et al., 1994).  
Chronic Infection and Epidemiology 
 
It has been established that the age at which an individual is infected is a strong 
indicator whether or not that individual will develop chronicity. Children born to 
infected mothers who are consequently infected vertically or perinatally are the 
most likely to develop chronic HBV and do so in 90% of the cases (Mahoney et 
al., 1993; WHO, 2002). Young children between the ages of one and five who 




risk of 30% compared to adults who only become chronically infected in 1-5% 
of cases (WHO, 2002). In addition to age, immunocompromised individuals are 
also at a greater risk of developing chronic HBV (Liaw, 1998). HBV is 
transmitted when blood, semen, or other body fluid infected with HBV enters the 
body of an uninfected individual (WHO, 2002).  
Chronic infection is a more global threat than acute, in terms of mortality and 
morbidity. It is estimated that 350 million individuals worldwide are chronically 
infected with HBV, but these numbers are difficult to verify as the majority of 
the carriers are asymptomatic and concentrated in the developing regions of Sub-
Saharan Africa and Asia (WHO, 2002; Franco et al., 2012). In most cases 
chronic infection goes undetected, however 20-30% of patients develop cirrhosis 
of the liver and this can lead to hepatocellular carcinoma (HCC). The 
geographical epidemiology of HCC and chronic HBV follow the same pattern, 
and additionally HCC is the leading cause of HBV induced mortality (WHO, 
2002).  
HBV Infection Mechanism 
 
Hepatitis B virus enters the host hepatocyte utilizing the sodium taurocholate 
cotransporting polypeptide (NTCP) on the surface of liver cells (Yan et al., 
2012). It proceeds to replicate in the host hepatocyte, involving the formation of 
covalently closed circular DNA (cccDNA) that serves as a transcriptional 
template within the host nucleus yielding viral mRNA, which then traverses to 
the cytoplasm and is translated into viral proteins (Tuttleman, Pourcel, & 




replication, transcribing viral RNA into DNA (Summers & Mason, 1982; Wang 
& Seeger, 1992). A major challenge for the host immune response is detecting 
and clearing the cccDNA inside infected hepatocytes.  
HBV Immunity 
 
Control and clearance of viral infections requires both a potent innate and 
adaptive immune response. The CD8 and CD 4 T cells of the adaptive immune 
system play a major role in controlling hepatitis B viral replication (Das & 
Maini, 2010; Zhai, Busuttil, & Kupiec-Weglinski, 2011). The innate response 
does not appear to be extensively involved, however the details of its role in viral 
control and liver pathogenesis need to be better elucidated (Chisari & Ferrari, 
1995; Das & Maini, 2010; Han, Zhang, Zhang, & Tian, 2013). Indeed, it appears 
that HBV manages to escape detection by the innate response; studies have 
reported a lack of type I interferons detected in infected hosts during the early 
stages of infection (Dunn et al., 2009; Wieland, Thimme, Purcell, & Chisari, 
2004). The adaptive immune response is instead clearly important for viral 
control. Patients who are able to control HBV acute infection are able to mount a 
robust HBV-specific T cell response that is usually detected 4-7 week after 
infection (Fisicaro et al., 2009; Webster et al., 2000). Even though antibodies are 
important for successive viral control, HBV-specific CD8 T cells play a major 
role in the clearance of HBV infected hepatocytes through lysis of infected 
hepatocytes, but also with non-cytopathic mechanisms mediated by IFN-γ and 
TNF-α (Bertoletti & Maini, 2000; Maini et al., 2000; Penna et al., 1991; Guidotti 




robust HBV-specific T cell response. The T cell response in CHB patients is 
usually defective both in quantity and in quality. HBV-specific CD8 T cells are 
present at a low frequency and unable to produce cytokines and proliferate (T 
cell exhaustion) in CHB patients. However, also in CHB patients, the magnitude 
of the HBV-specific T cell response correlates with viral control and not liver 
damage. The frequency of HBV-specific CD8 T cells both in the blood and in 
the liver is higher in patients with a low level of HBV replication than in CHB 
patients with high replication levels, suggesting that these cells are more 
important to viral control than liver damage (Maini et al., 2000).  
Pathology in Chronic Infection 
 
Pathology in chronic HBV patients is due to intrahepatic inflammatory events 
that can fluctuate in relation to viral replication and the host-immune response. 
Increased transaminase (ALT) levels are associated with liver damage, which 
fluctuate over time. Severe episodes of hepatic damage, which indicates 
exacerbations of disease, are called hepatic flares. They are characterized by 
increased HBV replication (108-109) and ALT 3-4 times the normal limit; which 
is part of the natural history of the disease. In the course of natural HBV 
reactivation and hepatic flare, concurrent viral or bacterial infection, 
immunosuppression, HBV treatment interruption and cancer chemotherapy have 
all been linked to reactivation (Gupta, Govindarajan, Fong, & Redeker, 1990; 
Perrillo, Campbell, Sanders, Regenstein, & Bodicky, 1984; Kim & Kim, 2014; 
Liaw, 1998). Furthermore, pregnancy may also be a risk factor for subsequent 




It is traditionally believed that HBV pathology is caused by the cytotoxic CD8 T 
cell response and this results in ALT levels five-fold that of the normal limit 
(Tsai et al., 1992; Yang et al., 1988), however there has been no substantial 
evidence behind these claims. As we discussed above, CD8 T cells can control 
HBV replication with a non-cytopathic mechanism mediated by cytokines and 
the HBV-specific T cell response correlates with viral control and not with liver 
damage (Guidotti et al., 1999; Maini et al., 2000). When assessing the CD8 T 
cell infiltration in those who control viral replication without hepatic injury and 
those who experience liver pathology, similar intrahepatic levels of HBV-
specific CD 8 T cells were found (Maini et al., 2000). In contrast, the number of 
total non-specific T cells infiltrating the liver were higher in subjects with liver 
inflammation, supporting the hypothesis that antigen-non-specific T cells and 
other inflammatory cells, like macrophages or NK cells, play a significant role in 
hepatocyte death and liver inflammation (Bertoletti & Maini, 2000; Maini et al., 
2000; Zheng, Wang, Tsabary, & Chen, 2004).  
HBV Antiviral Treatment 
 
Current treatment for patients with chronic HBV infection are utilizing two 
categories of drugs: interferon-alpha (IFN-α) based therapy and nucleos(t)ide 
analogues.  
IFN-α-based therapy has both an immunomodulatory mechanisms of action 
and a direct antiviral effect on the infected hepatocytes (Thimme & Dandri, 
2013). It is not clear which mechanism contributes to the beneficial effects 




therapy (Werle-Lapostolle et al., 2004). It appears to be enhancing the innate 
response through the stimulation of NK cells as well as acting directly on the 
cccDNA within the infected hepatocytes (Micco et al., 2013; Lutgehetmann et 
al., 2010). It has been shown that the effect on the adaptive response is limited, 
as treatment is not able to increase the CD 8 T cells needed for viral control in 
natural infection (Maini & Schurich, 2014). By enhancing cell-mediated 
immunity in host cells and suppressing HBV expansion, IFN-α-based therapy 
appears to be efficacious in reducing the rates of chronic HBV and HCC 
(Papatheodoridis, Manesis, & Hadziyannis, 2001; R. P. Perrillo et al., 1990; van 
Zonneveld et al., 2004). The side effects associated with IFN-α-based therapy are 
also important to note, as patients may feel unwell when they start treatment and 
experience hair loss, autoimmunity, emotional instability, and bone marrow 
suppression in some cases (Kwon & Lok, 2011). 
Nucleos(t)ide analogues block viral replication by interfering with the HBV 
reverse transcriptase enzyme in the host cell cytoplasm required by HBV to 
complete viral replication (Papatheodoridis, Dimou, & Papadimitropoulos, 
2002). Treatment with nucleos(t)ide analogues has shown to limit the production 
of new virions, reducing the intrahepatic inflammation and consequently 
cirrhosis of the liver and the incidence of HCC (Chang et al., 2010; Hadziyannis 
et al., 2006; S. S. Kim et al., 2014). As it purely exerts its effects on the reverse 
transcriptase enzyme, the cccDNA remains in the host cell leading to viral 
rebound upon the discontinuation of treatment. There are risks associated with 




IFN-α-based therapy. Tenofovir has been linked to nephrotoxicity and renal 
tubular dysfunction, although clinically modest, statistically significant (Cooper 
et al., 2010) as well as to the emergence of resistance with Lamivudine and 
Tenofovir (Zoulim, 2011). Lamivudine is widely known to have a very safe 
pharmacological profile, however in a study of chronic HBV patients, 10% of 
the subjects were found to have an increase in the baseline ALT of three to ten 
times the baseline value (Dienstag et al., 1999). Lamivudine has a very low 
barrier to resistance, which is why patients are sometimes treated with a 
combination of Lamivudine and Tenofovir, increasing the barrier to resistance. 
In summary, these treatments have an excellent efficacy to block HBV-
production, but upon stopping, the rate of disease relapse is very high as more 
than 45% of the patients are not able to achieve sustained viral control (HBV-
DNA 2000 copies/mL, normal ALT) within the first year (Hadziyannis, 










Introduction of study 
In our study we aim to increase our understanding of the events preceding and 
during viral rebound induced by therapy withdrawal. Through the longitudinal 
assessment of virological and immunological parameters of patients who are 
initially on combinational therapy with Lamivudine and Tenofovir, then 
monotherapy and then complete therapy withdrawal, we hope to elucidate factors 
associated with viral control upon therapy withdrawal. Virologically, we will 
quantify the HBeAb, HBsAg, and HBV-DNA in the serum. To understand the 
immunological events surrounding therapy withdrawal and viral control, we will 
perform a comprehensive analysis of HBV-specific T cells in the periphery of 
patients who experience therapy withdrawal induced hepatic flares and those 
who do not. Furthermore, we will assess an assortment of serum cytokines: IL-
1β, IL-6, TNF-α, CXCL-8, CXCL-10, and IL-10; utilizing the unique 
opportunity to analyse separate chronological events: 1) during therapy 2) 
leading up to an increase in viral replication and 3) during the exhibition of the 
hepatic flare. Together, these assessments will contribute to understanding why 
some patients experience viral rebound upon treatment discontinuation and bring 
us closer to being able to identify chronic HBV patients who can safely 








MATERIALS AND METHODS 
 
Patients 
Eight patients with chronic HBV were studied. Samples were collected 
longitudinally over two years at monthly intervals. The subjects were on 
combinational therapy with nucleos(t)ide analogues for at least one year, 
Tenofovir and Lamivudine, then monotherapy for 48-54 weeks and eventually 
complete withdrawal under close clinical monitoring. Each patient met the 
clinical and virological criteria of chronic HBV through the presence of hepatitis 
B surface antigen (HBsAg) for more than six months and HBV-DNA levels 
greater than 107 copies/ml. Peripheral blood mononuclear cells (PBMC) were 
collected every 4 weeks for two years; preceding the withdrawal of their first 
therapy, TDF, and subsequently LAM withdrawal. The PBMC were also 
collected during the complete absence of treatment and during the onset of the 
hepatic flare. This study was approved by the Singapore Ethics Committee. 
Virological Analysis 
The HBsAg , HBeAg and anti-HBe were measured by commercial enzyme 
immunoassay kits (Abbott Labs, IL, USA; Ortho Clkinical Diagnostic, Johnson 
& Johnson, DiaSorin, Vercelli, Italy). Serum HBV-DNA was quantified by PCR 
(Cobas Amplicor test; Roche Diagnostic, Basel, Switzerland).  
Longitudinal Cytokine Analysis 
Soluble composite array cytokines were measured longitudinally in the sera of 





Peptides corresponding to the envelope and core regions of the HBV proteome 
were used to stimulate the patient PBMC. These peptides were synthesized by 
and purchased from Mimotopes (Victoria, Australia) or from Massachusetts 
General Hospital. The two peptide panels consists of 313 15mer peptides, with 
ten of the residues overlapping. The peptides have been analysed by mass 
spectrometry and are verified to be more than 80% pure. Four different pools 
were prepared covering different regions of the envelope and core regions of the 
HBV proteome: Core, Env1, Env2, Protein X. The Core protein (15mer) was 
prepared in a nine by eight matrix and there were nine peptides in each pool. 
Each of the Env proteins was prepared in a nine by nine matrix, resulting in nine 
peptides for each pool. The X protein was pooled in a nine by eight matrix, 
therefore eight peptides a pool. All peptides were prepared in a matrix so that 
each peptide is present in two distinct pools, as previously done by Tan et al., 
2008. The peptides were dissolved in DMSO at 40mg/ml and prior to use diluted 
to 0.2mg/mL in AIM-V (Invitrogen, Carlsbad, CA).  
Analysis of the presence of virus-specific T cell lines 
The presence of HBV-specific T cells was analyzed using intracellular cytokine 
staining, testing for the presence of IFN-γ, IL-2, TNF-α production in cells after 
in vitro expansion with HBV-specific peptides covering the envelope and core 




10-day in-vitro expansion 
The ten-day expansion was performed to detect circulating HBV-specific T cells 
in the periphery. The PBMC samples were thawed using RPMI media with 10% 
FBS. Cells were counted and 20% were pulsed with a 10µg/ml of each the HBV 
peptides (Env 1, Env 2, precore/core, protein X) for 1 hour at 37C. The quality of 
the PBMC after thawing varied across time points. The cells were then mixed 
and plated onto a 96-well plate in AIM-V, 2% human AB serum supplemented 
with 20 IU/ml interleukin-2 (IL-2, R&D systems, Abingdon, UK). The plate was 
then placed into the incubator and left for 10 days.  
For the healthy control, the PBMC were stimulated with CMV, EBV and Flu 
peptides instead of HBV peptides. This subject served as a positive control to 
provide verification of the expansion protocol used, as this subject has 
circulating T cells specific for CMV, EBV, and Flu. 
After day 10 of in vitro expansion, each condition was prepared with HBV 
peptide pool, 10ng/ml phorbol myristate acetate and 100ng/ml ionomycin, or left 
unstimulated. Each was prepared AIM-V 2% human AB serum, and 10µg/ml 
brefeldin A (Sigma-Aldrich, St. Louis, MO). An anti-CD107a fluorescein 
isothiocynate (FITC) antibody (BD Biosciences, San Jose, CA) was added to 
each condition to assess the cellular degranulation, serving as a marker testing 
effector cell activity. The plate with each condition was then left in the incubator 
for 5 hours, enabling the brefeldin A (Sigma-Aldrich, St. Louis, MO) to inhibit 




Intracellular cytokine staining  
The presence of virus-specific T cells was tested by intracellular cytokine 
staining (ICS). The ICS was performed on the cells after the ten day expansion. 
After the 5 hour incubation period, cells were washed with staining buffer (PBS 
with 0.5% BSA, 0.02% sodium azide) and stained with anti-CD3 V450 (BD 
Biosciences, San Jose, CA), anti-CD4 Qdot655 (Life Technologies, Carlsbad, 
CA) and anti-CD8 V500 (BD Biosciences, San Jose, CA) for 30 minutes in the 
dark on ice. They were then washed, fixed and permeabilized by incubating them 
with Cytofix/CytopermTM solution (BD Biosciences, San Jose, CA) for 20 
minutes on ice, in the dark. This prepares the cells for the intracellular 
antibodies. The cells were washed and anti-IL2 peridinin chlorophyll protein 
(PerCP) Cy5.5 (BD Biosciences, San, Jose), anti-INFγ allophycocyanin (APC) 
(BD Biosciences, San Jose, CA) and anti-TNFα phycoerythrin (PE) (BD 
Biosciences, San, Jose), was added and the cells were left on ice for 30 minutes 
in the dark. The cells were then measured using the BD™ LSRII Flow 
Cytometer and analysed using FlowJo software (FLOWJO, Ashland, OR).  
Statistics 
To test the statistical significance of the results, the non-parametric Mann-
Whitney test was used. Only when the P-value generated by linear regression 
analysis and the Mann-Whitney test was equal to or less than 0.05 was it 







To investigate whether peculiar immune profiles of CHB patients are associated 
with their ability to control HBV replication after NA therapy interruption we 
collected sera and PBMC of CHB patients during and after antiviral viral therapy 
every 4 weeks for a total period of approximately two years (figure 1). At all the 
different time points we performed virological (HBsAg and HBV-DNA) and 
clinical (ALT) analysis and the following immunological quantification: 1) 
determination of the presence and frequency of HBV specific T cells specific for 
the envelope and core regions of the HBV proteome; 2) Analysis of the ability of 
T cells (CD4+ and CD8+) to produce IFN-γ, IL-2, CD107a and TNF-α after 
stimulation with PMA + ionomycin; 3) Direct analysis of the concentration of 
IL-1β, Il-6, TNF-α, IFN-α, CXCL-8, CXCL-10 and IL-10 cytokines in sera.  
Figure 1 shows the different virological and clinical profiles of the 8 studied 
patients. Patients were on long-term combinational therapy with tenofovir (TDF) 
and lamivudine (LAM) for at least one year at which point they switched to 
monotherapy at week 0 and after 44-54 weeks they discontinued NA therapy. All 
patients maintained viral control while under combinational (LAM+TDF) and 
monotherapy (LAM) at 102 – 103 copies of HBV-DNA/ml. Upon the 
discontinuation of treatment six patients (patient 3, 4, 5, 6, 7, 8) experienced 
viral rebound (109-1010 copies/ml) and two patients (patient 1, 2) maintained 
viral control (102 -103 copies/ml) (figure 1).  
We first comprehensively assessed whether circulating CD8 and CD4 T cells 




control viral replication after NA discontinuation. Previous work by Tan et al. 
(2010), performed in a similar patient cohort, has shown that the presence of 
HBV-specific T cells was associated with viral control. In our patient cohort, we 
stimulated patient PBMC for 10 days with peptide pools covering the envelope 
and core regions of the HBV proteome. The production of IFN-γ, TNF-α, IL-2, 
and CD107a was used to assess T cell functionality.  
Despite such a comprehensive analysis, we were unable to detect the presence of 
HBV-specific T cells both in patients that control viral replication after NA stop 
(patient 1 and 2) and in patients with viral rebound (patient 3,4,5,6,7, 8) (figure 
2). Flow cytometry data of a representative patient showing the quantification of 
HBV specific CD8 T cells is shown in figure 3.  
To confirm that our method of detection of virus-specific T cells was functional, 
PBMC of a healthy subject were stimulated with peptides corresponding to 
specific Flu, EBV and CMV epitopes. As shown in figure 4, this procedure was 
able to expand CMV, EBV and Flu specific T cells, demonstrating the 
functionality of our method and suggesting that the inability to detect HBV-
specific T cells in CHB patients in this study was due to the absence of such cells 
in the peripheral blood compartment. 
We then analyzed the functionality of the peripheral T cells to produce cytokines 
in response to stimulation by PMA-ionomycin (figure 5). While the production 
of both IL-2 and CD107a (figure 5A and 5B) by the T cells was not 
significantly different between patients who exhibit viral control (Patients 1-2) 




TNF-α (figure 5C and 5D) was different in the two patient groups. Higher 
frequencies of T cells able to produce IFN-γ and TNF-α were detected during the 
treatment period in the patients able to control HBV replication after NA 
interruption. Even though the results, due to the small sample size in our study, 
didn’t reach any statistical significance (analysis with the non-parametric Mann-
Whitney test), these data suggest that the overall ability to produce Th1 
cytokines might be linked to a successful treatment outcome.  
Thirdly, we studied serum cytokines in each of the patients during three separate 
chronological events: 1) on treatment with low viral DNA (≤ 104 copies/ml) and 
low ALT (≤ 70 IU/ml); 2) off treatment with an early increase in viral DNA and 
low ALT; 3) off treatment where 6 out of 8 patients display high levels of viral 
DNA and high levels of ALT.   
During treatment, as seen in figure 6, pro-inflammatory cytokines IL1-β, IL-6, 
TNF-α, IFN-α, and CXCL-8 were not found to be different in the serum of viral 
control patients and viral rebound patients. Furthermore, cytokines IL-10 (figure 
7A) and CXCL-10 (figure 7C) and were found to be above the limit of detection 
for Luminex, at similar levels. This suggests that the presence of these pro-
inflammatory and anti-inflammatory cytokines during treatment may not 
contribute to a viral control upon therapy withdrawal.  
After stopping treatment, we detected an increase in the values of CXCL-8 
(figure 6), IL-10 (figure 7A), and CXCL-10 (figure 7C) in patients 
experiencing HBV viral rebound and hepatic flares. Both IL-10 (figure 7A, 7B) 




signs of hepatic damage (ALT) and viral rebound. There was no change in the 
levels of IL1-β, IL-6, TNF-α and IFN-α upon treatment discontinuation in 
patients unable to control viral replication (figure 6). Taken together, these data 
confirmed previous observations that hepatic flares occurring after NA 
interruption are temporally associated with increased values of IL-10 and CXCL- 

















While current antiviral treatments for HBV are efficacious at blocking viral 
replication and reducing hepatic injury, the rate of viral rebound after the 
discontinuation of treatment is approximately 50% and for this reason CHB 
patients often require lifelong treatment (Hadziyannis, Sevastianos, Rapti, 
Vassilopoulos, & Hadziyannis, 2012). Little is known about the immunological 
events preceding viral rebound after therapy withdrawal, particularly in the 
subjects that are able to control HBV after therapy discontinuation. A previous 
analysis of a very small cohort of patients (n = 6) by Tan et al., (2010) has linked 
the ability to control HBV replication with the presence of a functional recovery 
of the HBV-specific T cell response.   
By understanding the immunobiological events surrounding viral control, we can 
contribute to identifying which CHB patients can safely discontinue their 
therapy. In this study we have proceeded to build on previous observations by 
studying a cohort of CHB patients (n = 8). These patients were under close 
clinical observation for two years, having previously been on therapy with 
Lamivudine and Tenofovir for at least one year. The patients stopped the first 
treatment (Tenofovir) at time point zero and after about 44-54 weeks stopped the 
second therapy (Lamivudine).  
Unlike Tan et al. (2010), we were unable to detect any HBV-specific T cells, not 
only in the periphery of CHB patients who experience viral rebound (n = 6) but 
also in the CHB who maintained viral control (n = 2). Tan et al. used a peptide 




longitudinal analysis of circulating T cells specific for the HBV core and 
envelope regions of the proteome, upon the discontinuation and in the weeks 
following, functional CD4 and CD8 T cells were consistently absent.  
The lack of detection of HBV-specific T cells is not unusual in patients with 
chronic HBV infection. HBV-specific T cells, particularly in patients with a very 
high viral load, are often undetectable when directly performing ex vivo analysis 
using different assays. Even when performing an in vitro expansion, when 
detectable, HBV-specific T cells are present at frequency around 0.02-0.03% of 
total CD8 T cells. Similar defects are also present in patients under antiviral 
therapy. Even though treatment with nucleos(t)ide analogues has been shown to 
replenish functional HBV specific CD8 and CD4 T cells, such reconstitution is 
transient and often only detectable during the first 1-2 months of therapy (Boni et 
al., 1998; Boni et al., 2003; Chen et al., 2011). A possible explanation for such 
lack of HBV-specific T cell recovery is the fact that even under NA therapy, 
CHB patients are characterized by the very high and constant production of 
HBsAg/HBcAg. The high level of HBV antigen presentation by the hepatocytes 
(that is not suppressed by NA therapy) maintains the state of HBV-specific T cell 
deletion and functional exhaustion that is characteristic of CHB patients, as the 
presentation of HBV antigens by hepatocytes is known to delete/exhaust HBV-
specific T cells (Isogawa, Chung, Murata, Kakimi, & Chisari, 2013). 
One other possible explanation is that the absence of functional HBV-specific T 
cells in the periphery of the patient cohort which exhibits viral control upon 




cells that might be present in these patients are not in the circulatory 
compartment in the liver.  
Despite the inability to detect any quantitative difference in the HBV-specific T 
cell response in our patient groups, the functional ability of T cells to produce 
IFN-γ and TNF-α after mitogen stimulation (PMA + ionomycin) was clearly 
superior in the patients who controlled HBV replication after NA withdrawal. 
Indeed, the T cells of these patients produce a higher quantity of TNF-α and 
IFN-γ after PMA + ionomycin stimulation, not only after NA discontinuation, 
but even during therapy. 
Even though the number of patients studied is clearly insufficient to draw any 
conclusions, this data suggests that the ability of T cells to produce cytokines 
with clear antiviral functions like IFN-γ and TNF-α, can be used as a possible 
diagnostic marker to define patients who can successfully stop therapy.  
In our study, we also longitudinally analyzed the different concentrations of 
cytokines and chemokines present in the sera of our patients. No differences 
could be detected in the profile of proinflammatory cytokines, as well as CXCL-
8, CXCL-10 and the anti-inflammatory cytokine IL-10 in patients who would go 
on to control viral replication and those who would not, after NA 
discontinuation.  
One other observation was that HBV rebound in CHB patients upon the 
discontinuation of therapy is independent of innate immune activation, as was 




consistently low (<15 pg/ml) in both patient cohorts, even when the HBV-DNA 
increased and the subsequent hepatic flare took place in the patients that 
displayed a lack of viral control upon HBV reactivation. It has been shown that 
HBV evades innate immune recognition through the receptors of the TLR family 
and also does not induce activation of NK cells early during infection (S. Wang 
et al., 2013; Wieland, Thimme, Purcell, & Chisari, 2004). Therefore, our results 
are in agreement with what has previously been established on the role of innate 
immunity and HBV reactivation.  
The role IL-10 plays in the control of HBV replication remains unclear. It was 
found to be elevated only in the patients experiencing viral rebound. Previous 
work in mice has demonstrated that through the up-regulation of IL-10, T cell 
functionality is impaired, contributing to viral persistence (Brooks et al., 2006). 
However, an increase in IL-10 was only observed upon the onset of the clinical 
hepatic flare, on average 13 weeks after therapy withdrawal. Therefore, it is most 
likely a homeostatic response to the inflammation associated with immune-
mediated hepatic injury and not playing a major role in inhibiting the favourable 
immune outcome in CHB.  
Interestingly, while CXCL-8 levels were similar during treatment, there was an 
increase in the detected levels of CXCL-8 after therapy withdrawal in the 
patients experiencing viral rebound. CXCL-8 has a chemotactic effect on T cells, 
granulocytes and NK cells, bringing them to the site of infection (Taub, Anver, 
Oppenheim, Longo, & Murphy, 1996). Such an increase in the levels of CXCL-8 




acute HBV infection (Dunn et al., 2007) and after NA interruption (Tan et al., 
2010).  
It is possible that this increase is due to the ability of HBV to transactivate the 
transcription of the CXCL-8 gene (Mahe et al., 1991). Through the activity of 
the CXCR1 receptor, CXCL-8 recruits NK cells to the site of infection 
(Campbell et al., 2001). CXCL-8 has also been shown to recruit granulocytes to 
the hepatic environment (Gehring et al., 2011). Furthermore, it has been 
suggested that CXCL-8 interferes with IFN-α antiviral activity (Khabar et al., 
1997). Taken together, as our patient cohort was small and there is not yet any 
clear data available on the precise role of CXCL-8 in HBV viral rebound, further 
work on CXCL-8 and the reactivation of HBV needs to be done. 
Lastly, we found that CXCL-10 increased with ALT in patients who had a 
rebound of hepatitis B viral replication upon the discontinuation of therapy. 
CXCL-10 is a chemoattractant for monocytes, macrophages and lymphocytes, 
bringing them to the site of infection in response to the proinflammatory 
cytokine INF-γ, which induces the secretion of CXCL-10 by several cell types 
(Dufour et al., 2002). Our work is in agreement with previous work by Tan et al., 
(2010) showing that CXCL-10 is temporally associated with the formation of the 
HF. The increase in CXCL-10 in our study was only seen upon an average of 13 
weeks following treatment discontinuation. Due to this temporal delay in the 
detection of CXCL-10 after NA withdrawal, CXCL-10 is most likely not playing 
a contributing role in the lack of viral control exhibited in this patient cohort. 




contribute to the pathogenesis of the HF (Kakimi et al., 2001; Lang et al., 2006). 
In addition, studies have shown that CXCL-10 might be inducing events which 
protect the liver during disease, in a hepatoprotective fashion (Bone-Larson, 
Hogaboam, Evanhoff, Strieter, & Kunkel, 2001; Colletti, Green, Burdick, & 
Strieter, 2000).  
In conclusion, through the sequential assessment of virological and 
immunological events, our study provides insight into which markers cannot be 
used to predict a favourable outcome upon treatment discontinuation. We 
demonstrate that even though HBV-specific T cells could not be detected in the 
periphery of both CHB patients who control viral replication and who do not 
upon the discontinuation of nucleos(t)ide analogue therapy, a better ability of T 
cells to produce the antiviral cytokines IFN-γ and TNF-α was associated with 
HBV control after NA discontinuation. Furthermore, we confirmed that levels of 
selected pro-inflammatory and anti-inflammatory cytokines did not differ after 

















Figure 1. Viral control and viral rebound in response to treatment 
discontinuation. HBV-DNA (●) and ALT (o) during combinational treatment, 
single treatment, and treatment withdrawal. Time points are represented relative 
to the first treatment discontinuation and the dotted line indicates complete 
therapy withdrawal. The red arrows indicate time points analysed for cytokine 
production by the HBV specific T cells. The red line indicates the lag time 






Figure 2. Mean frequency of CD8 T cells in CHB patients. Production of 
IFN-γ in CHB patients with viral control (patient 1 and 2) and viral rebound 
(patient 3-8) before and after antiviral therapy. PMA-ionomycin control (+), 
unstimulated control (-), and 10 day HBV-peptide stimulation (HBV-peptide). 







Figure 3. The presence of HBV specific T cells in viral control CHB patient 
during treatment (A) and after treatment discontinuation (B). The patient’s 
T cells were stimulated in the presence of Brefeldin A with or without peptides 
from the HBV proteome or with a positive control. The ICS was performed to 
detect INF-γ, CD107a, IL-2, and TNF-α, the plot is gated on CD3+ CD8+ cells. 









Figure 4. Presence of functional T cells in a healthy subject in response to 
stimulation with peptide epitopes. The T cells of a healthy subject were 
stimulated in the presence of Brefeldin A, with (or without) peptides or with a 
positive control. The peptides were: HCMVpp65 123-131 (IPSINVHHY) 
(denoted CMV); EBV EBNA 4NP (AVFDRKSDAK) (denoted EBV); Influenza 
AMP 58-66 (GILGFVFTL) (denoted Flu). The ICS was performed to detect 
















Figure 5. Mean frequency of CD8 T cells in response to PMA + ionomycin 
stimulation. Production of IL-2 (A), CD107a (B), IFN-γ (C) and TNF-α (D) in 
CHB patients with viral rebound (n=6) and viral control (n=2), before and after 
antiviral therapy. Rebound denotes patients with an increase in HBV-DNA upon 
treatment discontinuation and control denotes patients who maintain treatment 
levels of HBV-DNA upon treatment discontinuation. Treatment discontinuation 

















Figure 6. Pro-inflammatory longitudinal cytokine levels in chronic HBV 
patients. Cytokines from patients (n=8) were measured longitudinally by 
Luminex in response to treatment discontinuation. The mean cytokine 
concentration is shown during each stage. Pro-inflammatory cytokines IL-1β, IL-

















































Figure 7. Temporal relation of CXCL-10 and IL-10 with viral rebound. 
Serum concentrations CXCL-10 and IL-10 were measured using Luminex assay 
during various phases of treatment withdrawal. IL-10 (A) and CXCL-10 (C) in 
response to treatment discontinuation is depicted during different stages of viral 
rebound and hepatic injury, on the left figure. Hepatic injury (ALT) and IL-10 (A 
on the right) were analysed by a linear regression model (R2 = 0.7193, p < 
0.0001). Hepatic injury and CXCL-10 (C on the right) were analysed by a linear 
regresssion model (R2 = 0.7157, p < 0.0001). The dotted line indicates the 95% 
confidence interval. Two representative patients (B) are shown with HBV-DNA 
(●) and clinical ALT (o) in relation to IL-10. Two representative patients (D) are 
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